Suppr超能文献

非洲不合格、伪造、无许可证和未注册药品的流行情况及其相关因素:一项系统综述

Prevalence of substandard, falsified, unlicensed and unregistered medicine and its associated factors in Africa: a systematic review.

作者信息

Asrade Mekonnen Biset, Getie Yizengaw Muluabay, Chanie Worku Minichil

机构信息

Department of Pharmacy, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.

Biochemistry, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.

出版信息

J Pharm Policy Pract. 2024 Jul 15;17(1):2375267. doi: 10.1080/20523211.2024.2375267. eCollection 2024.

Abstract

BACKGROUND

Substandard, falsified, unlicensed, and unregistered medicines pose significant risks to public health in developed and developing countries. This systematic review provides an overview of the prevalence of substandard, falsified, unlicensed, and unregistered medicine and its associated factors in Africa.

METHODS

Articles published from April 2014 to March 2024 were searched in Google Scholar, Science Direct, PubMed, MEDLINE, and Embase. The search strategy focused on open-access articles published in peer-reviewed scientific journals and studies exclusively conducted in African countries. The quality of the studies was assessed according to the Medicine Quality Assessment Reporting Guidelines (MEDQUARG). This systematic review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA).

RESULTS

Of the 27 studies, 26 had good methodological quality after a quality assessment. Of the 7508 medicine samples, 1639 failed at least one quality test and were confirmed to be substandard/falsified medicines. The overall estimated prevalence of substandard/falsified medicines in Africa was 22.6% (1718/7592). The average prevalence of unregistered medicines was 34.6% (108/312). Antibiotics, antimalarial, and antihypertensive medicines accounted for 44.6% (712/1596), 15.6% (530/3530), 16.3% (249/1530), and 16.3% (249/1530), respectively. Approximately 60.7% (91/150) were antihelmintic and antiprotozoal medicines. Poor market regulatory permission, Free trade zones, poor registration, high demand, and poor importation standards contribute to the prevalence of these problems.

CONCLUSION/RECOMMENDATIONS: Substandard, falsified, and unregistered medicines are highly prevalent in Africa, and attention has not been paid to the problem. Antibiotics, antimalarial, anthelmintic, and antiprotozoal are the most commonly reported substandard, falsified, and unregistered medicines. A consistent supply of high-quality products, enhancement of registration, market regulatory permission, and importation standards are essential to counter the problems in Africa. Preventing these problems is the primary duty of every responsible nation to save lives.

摘要

背景

劣质、伪造、无许可证和未注册的药品在发达国家和发展中国家对公众健康构成重大风险。本系统评价概述了非洲劣质、伪造、无许可证和未注册药品的流行情况及其相关因素。

方法

在谷歌学术、科学Direct、PubMed、MEDLINE和Embase中检索2014年4月至2024年3月发表的文章。检索策略侧重于发表在同行评审科学期刊上的开放获取文章以及专门在非洲国家进行的研究。根据药品质量评估报告指南(MEDQUARG)评估研究质量。本系统评价按照系统评价和Meta分析的首选报告项目(PRISMA)进行报告。

结果

在27项研究中,经过质量评估,26项研究具有良好的方法学质量。在7508份药品样本中,1639份至少一项质量检测不合格,被确认为劣质/伪造药品。非洲劣质/伪造药品的总体估计流行率为22.6%(1718/7592)。未注册药品的平均流行率为34.6%(108/312)。抗生素、抗疟药和抗高血压药分别占44.6%(712/1596)、15.6%(530/3530)、16.3%(249/1530)和16.3%(249/1530)。约60.7%(91/150)为抗蠕虫药和抗原虫药。市场监管许可不力、自由贸易区、注册不善、需求高和进口标准差导致了这些问题的流行。

结论/建议:劣质、伪造和未注册药品在非洲非常普遍,且该问题尚未得到关注。抗生素、抗疟药、抗蠕虫药和抗原虫药是最常被报告的劣质、伪造和未注册药品。持续供应高质量产品、加强注册、市场监管许可和进口标准对于应对非洲的这些问题至关重要。预防这些问题是每个负责任国家拯救生命的首要职责。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a8a/11251437/8a181defccd6/JPPP_A_2375267_F0001_OC.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验